Fig. 2.

A schematic overview of all development-stage DARPin^® drug candidates depicted on the two dimensions “degree of novel biology” vs. “degree of novel drug concept” on the drug development programs in the context of the three-horizon strategy of Molecular Partners. A first-horizon program such as abicipar is built on known biology and takes advantage of the favorable DARPin^® drug properties for the generation of a “biobetter compound.” Second-horizon programs such as MP0250 and MP0274 are based on biology that has been validated in third-party phase II clinical trials; at the same time, they are multidomain drug candidates, a key strength of the DARPin^® platform. In third-horizon programs, biology may be less validated and novel drug concepts may be applied, as illustrated by MP0310 (see Fig. 5) and MP0317